The effects of practolol, a new beta-adrenergic blocking agent, and propranolol were studied in volunteers. At rest, practolol caused a very small reduction in cardiac index (CI), 190 ml, P < 0.25, and preejection period (PEP) lengthened 3 msec, P < 0.025. In contrast, propranolol caused a reduction in CI of 770 ml, P < 0.001. Heart rate (HR) slowed 10 beats/min, P < 0.001, stroke volume index (SVI) fell 6 ml, P < 0.005, PEP lengthened 16 msec, P < 0.001, and peripheral vascular resistance (PVR) increased 419 dynes-sec-cm-5, P < 0.001. Practolol reduced the increase in CI caused by an isoproterenol infusion by 65%, P <0.005, by blocking the increase in HR by 73%, P < 0.05. Practolol also reduced the shortening of PEP and LVET caused by isoproterenol. PVR decreases due to isoproterenol were not blocked by practolol although they were slightly attenuated, P < 0.025. Practolol reduced the increase in CI caused by exercise by 22%, P < 0.05, by blocking the increase in HR by 29%, P < 0.01. Practolol also reduced the increase in tension-time index due to exercise by 25%, P <0.025.
levels impairment of resting ventricular performance occurs while coronary blood flow increases. The effects of isoproterenol on peripheral vascular resistance are not blocked by practolol. It was not possible to assess the potency ratio of practolol and propranolol in these studies because the slope of their doseresponse curves for heart rate and cardiac contractile force is different.1 3 These animal data do indicate that practolol in low and intermediate dose ranges is one-fourth as effective as propranolol in terms of its ability to block isoproterenol-induced tachycardia.
Brick and co-workers4 have shown in volunteers that the dose-response curve of practolol as a blocker of catecholamine infusion and exercise tachycardia is quite flat when compared to the dose-response curve of propranolol; as the dose of practolol increases, the response curve flattens further when compared to propranolol.
A trial of gradually increasing doses of practolol has been conducted on volunteers in this laboratory, employing doses of 0.15, 0.30, 0.60, and 1.20 mg/kg. As the dosage was increased beyond 0.30 mg/kg there was no increase in the effectiveness of practolol in terms of chronotropic or inotropic blocking effect, thus confirming that at these very large dose levels the dose-response curve continues to be essentially flat. 5 The purpose of the present study was, first of all, to compare the effects of practolol to those of propranolol on the performance of the normal human heart; secondly, to determine the capacity of practolol to block the changes in human cardiac performance and peripheral vascular resistance caused by a standard isoproterenol infusion; and thirdly, to determine the capacity of practolol to block the effects of exercise on cardiac work and oxygen requirements by observing differences in cardiac performance and pressure-time relationships.
Methods Seventeen healthy, ambulatory men between the ages of 22 and 30 years volunteered for early afternoon study. Arterial pressure was monitored through a polyethylene cannula (Clay Adams PE 160), 20 cm in length, and central venous pressure was monitored through a polyethylene catheter (Clay Adams PE 50), 90 cm in length, which had been introduced percutaneously from an antecubital vein into the right atrium. The indirect carotid pressure pulse was recorded from a strain gauge held to the carotid pulse in the neck, and heart sounds were recorded from a precordial microphone. A polybeam recorder (Electronics for Medicine DR 12) was used to record arterial and venous pressure, the carotid pulse contour, the heart sounds, and the electrocardiogram at 100 mm/sec paper speed. Mean systolic pressure was determined by planimetry, and left ventricular ejection time was determined by averaging the time from the onset of the upstroke to the incisura of five carotid pressure pulse complexes. The preejection period was calculated by subtracting the left ventricular ejection time from the Q-A2 interval in the same five consecutive complexes. Cardiac output was determined from duplicate indicator dilution Circulation, Volume XLV, January 1972 curves. The peripheral vascular resistance and tension-time index were calculated.
In the first part of the experimental protocol, control measurements were made, and eight of the volunteers were given propranolol, 0.15 mg/kg intravenously over 2 minutes. Nine other volunteers were given practolol,* 0.60 mg/kg intravenously over the same period of time. Between the fourth and seventh minute after infusion of the drug the measurements were repeated. Comparisons of the effects of propranolol and practolol on resting cardiac proformance were made.
In the second part of the experimental protocol, seven subjects were selected who were to receive practolol. After control measurements, isoproterenol was infused at a constant rate of 0.025 ,g/kg/min, and during the fourth minute of the infusion measurements were repeated. Thereafter, each subject was rested for 30 minutes or longer, and new control measurements were made to assure that the effects of isoproterenol had subsided. Then practolol was infused, three subjects receiving 0.30 mg/kg, one receiving 0.45 mg/kg, and three receiving 0.60 mg/kg. Measurements were repeated between the fourth and sixth minute. Six minutes after practolol infusion the isoproterenol challenge was repeated, and measurements were made between the tenth and twelfth minute after practolol administration. Comparisons of the effects of isoproterenol alone and isproterenol in the presence of practolol on cardiac performance were made.
In the third part of the experimental protocol, six subjects were selected who were to receive practolol. Three received 0.30 mg/kg, and three received 0.60 mg/kg. The protocol was identical to the isoproterenol infusion protocol, except that each subject performed 50 watts of exercise on a bicycle ergometer rather than receiving infusions of catecholamine. ( fig. 2 ). In contrast, propranolol administration caused a 770 ml/min reduction in cardiac index. Heart rate decreased 10 beats/min, and stroke volume index decreased 6 ml ( fig. 1 ). There was also no change in mean arterial pressure after propranolol infusion. However, cardiac output did fall 1,490 ml/min, and calculated peripheral vascular resistance increased 419 dynes, from 1,249 to 1,668 dynessec-cm--! ( fig. 2 ).
Propranolol caused a 21 ml/systolic second reduction in the mean rate of left ventricular ejection index. In contrast, no change in ventricular ejection rate index was observed following practolol infusion. Neither practolol nor propranolol caused prolongation of left ventricular ejection time, so these differences are due to the different effects of the two drugs on stroke volume index. Propranolol infusion caused preejection period to increase 16 msec, from 90 to 106, whereas practolol caused preejection period to increase only 3 msec, from 101 to 104 ( fig. 2 ).
In table 1 are summarized the hemodynamic effects of isoproterenol infusion before and after practolol administration in seven subjects. The initial isoproterenol infusion caused heart rate to increase 26 beats/min, and stroke volume index increased 7 ml. After practolol administration, an identical isoproterenol infusion caused a heart rate increase of only 7 beats/minute and stroke volume index increase of 6 ml, essentially the same as that seen prior to beta blockade ( fig. 3) Figure 5 Exercise (50 watts) caused CI to increase 3,100 ml. HR increased 46/min, and SVI increased 10 ml. Following practolol, exercise caused CI to increase 2,430 ml. HR increased 33/min, and SVI again increased 10 ml.
cardiac patients causes slowing of resting heart rate. A possible explanation for this apparent disparity lies in the different levels of resting sympathetic activity found in volunteers and cardiac patients. It is likely that the patient group experiences a higher level of cardiac sympathetic drive at rest and therefore is more responsive to the negative chronotropic influence of practolol than the group of normal subjects.
In contrast, beta-adrenergic blockade with propranolol caused a substantial reduction in resting cardiac index. A decline in heart rate of 10 beats/min and a decrease in stroke volume contributed to the reduction in flow. The magnitude of decrease in heart rate following propranolol administration has been shown to be dependent on the level of basal prevented by atrial pacing, propranolol infusion still causes a reduction in stroke volume, thus demonstrating the additional intriinsic cardiac depressant effect of propranolol, the quinidine-like effect." When compared to propranolol, practolol has less effect on heart rate and stroke volume in the normal heart, and practolol does not exhibit any intrinsic cardiac depressant characteristics at rest. This difference has significant implications in terms of the relative safety of the two drugs for patients in heart failure.
Isoproterenol infusion caused an increase in cardiac index by increasing heart rate and stroke volume. Practolol reduced the isoprot erenol-induced tachycardia but it had no effect on stroke volume increases. Exercise on an ergometer caused cardiac index to double by increasing heart rate and stroke volume. Following beta blockade with practolol anl identical increment in stroke volume occurred with exercise, but heart rate increases were reduced by 28%. Thus, the increment in stroke volume inidex caused by isoprotereniol infu~sioni anid exercise was preserved followvinig practolol blockade, and the primary effect of practolol was on the rate response to isoproterenol and exercise. In this sense, practolol may be viewed as having more chronotropic than inotropic blocking effect in the normal heart.
Effects on Ventricular Performance
Preejection period has proven to be a reliable index of ventricular performance when aortic diastolic pressure remains constant. There is a high degree of correlation betveen preejection period and true isovolumic contraction time in man, and changes in preejection period accurately reflect changes in isovolumic contraction time.12 13 The mean rate of left ventricular ejection, calculated from stroke volume and the duration of ejection, may also be viewed as an indicator of ventricular performance. At rest, propranolol caused a substantial prolongation of preejection period and a reduction in ventricular ejection rate. In contrast, practolol had no such substantial effects on these two parameters at rest. However, practolol did reduce by 50% the striking degree of preejection period shortening as well as reduced by a similar amount the increase in ejection rate that occurred during isoproterenol infusion. Thus, in addition to its primary chronotropic blocking effect, practolol also manifests an inotropic blocking effect against isoproterenol, even though this is not reflected by changes in stroke volume. More importantly, from the standpoint of clinical application, practolol did not interfere with the shortening of preejection period and augmentation of ejection rate associated with exercise, and so this drug has no direct depressant effect on stroke volume or ventricular performance at rest or during exercise in the normal heart. Normal persons experience a reduction in peripheral vascular resistance during isoproterenol infusion, and in these studies peripheral resistance fell 491 dynes. Practolol, at most, only slightly attenuated the fall in peripheral resistance caused by isoproterenol infusion. Thus, practolol, in the doses used, does not appear to be an effective blocker of peripheral vascular receptors. This is in contrast to the known ability of propranolol to completely block the peripheral vascular effects of isoproterenol. '4 During exercise the mean arterial pressure rose 25-mm Hg as flow increased 5,910 ml/min and peripheral vascular resistance fell 448 dynes. Following practolol administration a fall in peripheral resistance of the same magnitude, 481 dynes, P > 0.10, occurred while mean pressure rose 13 mm Hg and flosy increased 4,630 ml/min. Since resistances ws,ere similar during control exercise, 792 dynes, aind during exercise with practolol, 827 dynes, the magnitude of increase in mean arterial pressure with exercise is related to the magnitude in increase in flow and not related to differences in peripheral resistance.
Effects on Pressure-Time Relationships
It is well established that increases in heart rate contribute greatly to increases in pressuretime products, and if exercise-induced increases in heart rate can be reduced, then pressure-time relationships will be more favorable for preventing ischemic cardiac pain.15 The ability of practolol to reduce the heart rate during exercise suggests that it might be well suited for the treatment of angina. In these studies the control exercise increase in tension-time index was 1,757 mm Hg-sec/minute. Following cardiac beta blockade with practolol, tension-time index increased 1,314 mm Hg-sec/min with exercise, 75% of the control change. These differences are statistically significant but it is questionable whether or not they are of enoughl magnitude to permit clinically important increases in exercise tolerance in a patient with exertional angina. However, it should be kept in mind that cardiac patients do experience cardiac slowing with practolol, even at rest. It may be reasonable to speculate that practolol might cause a greater reduction in exercise tachycardia in the patient population than in our normal subjects and, thereby, cause a more impressive effect on myocardial oxygen consumption with exercise.
